Payment overview · 2025
General Payments
$104.67
6 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Land, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ABBEVILLE, GA · NPI 1972148708
Verified facts
What the public records show
CMS Open Payments records show Robert Land, PA received $104.67 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.20 | 20.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.65 | 18.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.41 | 16.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.70 | 15.9% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $15.89 | 15.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.82 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.67 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 77 |
| Losartan Potassium | Losartan Potassium | 199 | 65 |
| Lisinopril | Lisinopril | 177 | 52 |
| Potassium Chloride | Potassium Chloride | 175 | 60 |
| Meloxicam | Meloxicam | 165 | 62 |
| Gabapentin | Gabapentin | 144 | 57 |
| Omeprazole | Omeprazole | 138 | 42 |
| Metformin Hcl | Metformin Hcl | 131 | 52 |
| Furosemide | Furosemide | 126 | 43 |
| Carvedilol | Carvedilol | 120 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 32 |
| Nifedipine Er | Nifedipine | 99 | 28 |
| Montelukast Sodium | Montelukast Sodium | 95 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 27 |
| Jardiance | Empagliflozin | 89 | 24 |
| Famotidine | Famotidine | 85 | 26 |
| Mounjaro | Tirzepatide | 80 | 15 |
| Ozempic | Semaglutide | 80 | 13 |
| Tramadol Hcl | Tramadol Hcl | 78 | 23 |
| Sertraline Hcl | Sertraline Hcl | 75 | 23 |
| Trulicity | Dulaglutide | 75 | 12 |
| Trazodone Hcl | Trazodone Hcl | 73 | 23 |
| Spironolactone | Spironolactone | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 17 |
| Linzess | Linaclotide | 63 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 22 |
| Vraylar | Cariprazine Hcl | 59 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 20 |
| Simvastatin | Simvastatin | 58 | 18 |
| Buspirone Hcl | Buspirone Hcl | 57 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 12 |
| Glipizide | Glipizide | 48 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 20 |
| Eliquis | Apixaban | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Meclizine Hcl | Meclizine Hcl | 46 | 12 |
| Allopurinol | Allopurinol | 45 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 16 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 13 |
| Alprazolam | Alprazolam | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 16 |
| Ibuprofen | Ibuprofen | 38 | 14 |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | 14 |
| Valsartan | Valsartan | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Prednisone | Prednisone | 29 | 27 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | 12 |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Atenolol | Atenolol | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.67 · 6 records | Novo Nordisk Inc | AREXVY, FARXIGA, JARDIANCE, Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error